Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rab 32 Gene Polymorphisms in Leprosy Patients Treated with MDT
NCT06819449Recruiting
- Sponsor
- South Valley University
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of dapsone, rifampicin and clofazimine in leprosy (HD) (2 arms), sponsored by South Valley University. Primary endpoint: Treatment of leprosy at 6 Months. Started Dec 2024; status: recruiting.
02
Drugs
dapsonerifampicinclofazimine
03
Conditions
leprosy (HD)
Beyond the preview
Go deeper on NCT06819449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819449.